Zimmer Biomet (NYSE: ZBH) announced today that it received FDA 510(k) clearance for its Persona Revision SoluTion Femur.
Medical Device Network on MSN5d
FDA grants 510(k) clearance to Zimmer’s new revision knee implant componentThe US Food and Drug Administration (FDA) has granted 510(k) clearance to Zimmer Biomet's new revision knee implant component ...
Zimmer Biomet’s flagship robot, Rosa, is expected to make gains in the near future, CEO Ivan Tornos said at the Barclays 27th Annual Global Healthcare Conference. Mr. Tornos said adoption of the robot ...
Proficio Capital Partners LLC bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) during ...
Zimmer Biomet Holdings ... with its orthopedics division contributing around $2.3 billion. Its knee and hip implant segments saw underlying growth rates of 1.3% and 4%, respectively, over 2023.
In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Zimmer Biomet Holdings (ZBH – Research Report).
The Terminator actor teamed up with Zimmer Biomet to raise awareness about osteoarthritis, which affects more than 25 million ...
A Revision Knee Implant Alternative for Patients with Metal Sensitivities WARSAW, Ind., March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ...
The US Food and Drug Administration (FDA) has granted 510(k) clearance to Zimmer Biomet's new revision knee implant component, Persona Revision SoluTion Femur, to provide an option for individuals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback